Bipolar disorder

• 1. Introduction

  ›

  Bipolar disorder carries a statistic that stops most people cold: those diagnosed with it are 11.7 times more likely to die by suicide than the general population. On average, their lives are 12.9 years shorter. And yet roughly 1 to 3% of all people alive today will be diagnosed with it at some point in their lives. This is a condition that touches tens of millions of people worldwide, ranks sixth among all causes of disability globally, and still lacks a fully understood biological mechanism.

  What does it actually mean to live with bipolar disorder? How did medicine come to recognize it? And what does the science now say about its causes, its costs, and the gap between treatment and recovery? Those are the questions this documentary will work through.

• 2. The Shape of the Illness

  ›

  Bipolar disorder is defined not by sadness alone but by the relationship between extremes. A manic episode, by clinical definition, lasts at least one week of elevated or irritable mood severe enough to impair the ability to work or socialize. During that window, a person may experience grandiosity, racing thoughts, pressured speech that is difficult to interrupt, a sharply reduced need for sleep, and a pull toward impulsive or high-risk behaviors including excessive spending.

  Left untreated, a manic episode typically runs three to six months. In its most severe form, it can produce psychotic symptoms: a person may feel unstoppable, believe they have a special mission from God, or hold other grandiose delusions. Approximately 60 to 75% of people with bipolar I disorder have experienced psychosis at some point.

  Hypomania is the milder cousin. Defined as at least four consecutive days of elevated mood, it does not reach the threshold of impairing social or occupational functioning and does not require hospitalization. Some people find hypomania productive; others find it painful. But people who experience it tend to forget the effects of their behavior on those around them, and even when family members identify the mood shift, the individual will often deny anything is wrong.

  The depressive phase typically lasts far longer than the manic one. Persistent sadness, loss of interest in previously enjoyed activities, fatigue, changes in appetite or weight, and thoughts of death or suicide characterize this phase. Because bipolar disorder requires at least one manic or hypomanic episode to diagnose, many people are initially misdiagnosed with major depression and treated accordingly, often for years.

  Mixed states add another layer of complexity: episodes in which symptoms of both mania and depression occur at the same time. A person may hold grandiose thoughts while simultaneously feeling suicidal, a combination that researchers associate with heightened risk of self-harm because depressive emotions such as hopelessness can combine with the impulsivity of mania.

• 3. Genetics and Environment

  ›

  Genetic factors are estimated to account for 73 to 93% of the risk of developing bipolar disorder, making it one of the more heritable psychiatric conditions known. Identical twins share the diagnosis at a concordance rate of around 40%; fraternal twins share it at roughly 5%. When the definition is broadened to include either bipolar disorder or major depression, that concordance rises to 67% in identical twins and 19% in fraternal twins.

  The risk of bipolar disorder in first-degree relatives of someone diagnosed is nearly ten times higher than in the general population. Genome-wide association studies have identified several variants linked to the condition, including variants within the genes CACNA1C, ODZ4, and NCAN. In 2022, the AKAP11 gene was identified as the first gene directly linked to bipolar disorder through analysis of exome data from around 14,000 individuals with the condition, combined with data from an additional 24,000 people. Notably, AKAP11 interacts with the GSK3B protein, which is itself a molecular target of lithium, the drug most reliably associated with treating the disorder.

  Environmental factors shape the expression of that genetic risk. Between 30 and 50% of adults with bipolar disorder report traumatic or abusive experiences in childhood, which correlates with earlier onset, higher rates of suicide attempts, and more co-occurring conditions. A key mechanism proposed by researchers involves the hypothalamic-pituitary-adrenal (HPA) axis: early-life stress appears to cause HPA axis overactivation, which may contribute to the biological course of the disorder. Sleep deprivation can directly trigger mania in around 30% of people with bipolar disorder. Traveling across many time zones can destabilize the condition and precipitate manic or psychotic episodes.

  The "kindling" hypothesis offers a framework for how these influences interact: each stressful episode may lower the mood threshold, until episodes eventually begin occurring spontaneously without an obvious external trigger.

• 4. Diagnosis and Classification

  ›

  Bipolar I disorder requires at least one full manic episode; depressive episodes are common but not required for the diagnosis. Bipolar II disorder requires at least one hypomanic episode and one major depressive episode, but no full manic episode. Cyclothymia involves alternating hypomanic and depressive periods that do not meet the full criteria for major depressive episodes, persisting for at least two years in adults and one year in children and adolescents.

  The most widely used diagnostic criteria come from the American Psychiatric Association's DSM-5, published in 2013, and the World Health Organization's ICD-10. Outside the United States, ICD-10 criteria are more common in clinical practice; the DSM criteria predominate in international research. The DSM-5 introduced more detailed specifiers compared to its predecessor, and its influence has shaped the ICD-11's approach to the bipolar spectrum.

  Diagnosis depends on self-reported experience, observations from family and friends, clinician assessment, and medical tests to rule out other causes. Several conditions can produce symptoms that resemble bipolar disorder, including multiple sclerosis, traumatic brain injury, Wilson's disease, Huntington's disease, thyroid disorders, lupus, herpes encephalitis, and certain vitamin deficiencies including pellagra and vitamin B12 deficiency. Medications including antidepressants, prednisone, stimulants, and some antibiotics can also induce manic symptoms.

  Rapid cycling is a course specifier applied when four or more mood episodes occur within a single year. At some point in their illness, 25.8 to 45.3% of people with bipolar disorder experience rapid cycling. It is associated with the worst prognosis, higher rates of self-harm and suicide, and greater resistance to medication. The definition most cited in the literature traces back to the work of Dunner and Fieve.

• 5. Treatment Landscape

  ›

  Lithium carries the broadest evidence base of any treatment for bipolar disorder. It reduces the risk of suicide, self-harm, and death; it is preferred for long-term mood stabilization; and randomized controlled trials spanning more than 40 years support its effectiveness in reducing suicide among people with bipolar disorder or major depression. People with bipolar disorder who take lithium maintenance have a relative reduction in dementia odds of 49%, bringing rates close to that of the general population.

  Other mood stabilizers include valproate, carbamazepine, and lamotrigine. Valproate effectively treats manic episodes and has become widely prescribed. Carbamazepine is considered less effective than lithium or valproate for relapse prevention but shows some advantage in rapid-cycling bipolar disorder. Lamotrigine has demonstrated benefit particularly in severe depression and may carry fewer adverse effects than lithium, though it appears less effective at preventing recurrent mania. Both valproate and carbamazepine are teratogenic and require careful management in women of childbearing age; lithium is teratogenic in the first trimester but may be acceptable during that period when benefits and risks are weighed carefully.

  Atypical antipsychotics are effective for acute manic episodes and, for short-term treatment, appear superior to lithium and anticonvulsants. Several are FDA-approved specifically for bipolar depression, including lurasidone, quetiapine, olanzapine-fluoxetine combination, cariprazine, and lumateperone. Used together, atypical antipsychotics and mood stabilizers treat mania more quickly and effectively than either class alone.

  Antidepressant use in bipolar disorder remains contested. Certain classes carry a risk of triggering mania or accelerating cycling between phases. The FDA has approved five atypical antipsychotics specifically for bipolar depression, and these are generally preferred over antidepressants for augmenting mood stabilizers.

  Electroconvulsive therapy has demonstrated effectiveness in acute manic and depressive episodes, particularly when psychosis or catatonia is present, and is also recommended for pregnant women with bipolar disorder. The United Nations Committee on Rights of Persons with Disabilities has called for the abolition of institutionalization and forced treatments including sedatives, mood stabilizers, and electroconvulsive treatment.

  More than 75% of individuals with bipolar disorder inconsistently take their medications, making adherence one of the most significant factors in determining long-term outcomes. Among psychosocial approaches, cognitive behavioral therapy, family-focused therapy, and psychoeducation show the strongest evidence for relapse prevention.

• 6. Burden and Stigma

  ›

  In 2015, the United States spent approximately $202.1 billion on people diagnosed with bipolar I disorder alone. The United Kingdom spent approximately 5.2 billion pounds on the disorder in 2007. Around 40 to 60% of people with bipolar disorder are employed, while over 80% may take time off work for psychiatric reasons over any five-year period. One-third of people with bipolar disorder remain unemployed for a full year following a hospitalization for mania.

  As of 2021, bipolar disorder accounted for 183 years lived with disability per 100,000 people in the Americas, ranking 20th among all conditions tracked. The risk of death from unnatural causes is 7.3 times higher in people with bipolar disorder compared to the general population; from natural causes, 1.9 times higher.

  Stigma compounds the clinical burden. According to a systematic review by Latifian and others published in 2023, stigma causes people with bipolar disorder and their families to suffer severe psychological distress beyond the illness itself, including lower self-esteem, social deprivation, and reduced quality of life. Self-stigmatization is linked to lower functioning across multiple domains and greater symptoms of both depression and anxiety.

  A 2024 meta-analysis estimated that approximately 8% of homeless individuals globally have bipolar disorder, a rate several times higher than population averages. In the United States, 55% of veterans with bipolar disorder reported being homeless at some point in their lives. Disruptions in care from housing instability lead to higher rates of psychiatric hospitalization and worse long-term outcomes.

  In 2000, actress Carrie Fisher publicly disclosed her diagnosis and became one of the most prominent advocates working to reduce stigma around mental illness. Actor Stephen Fry, diagnosed at age 37, produced a 2006 documentary, Stephen Fry: The Secret Life of the Manic Depressive. Orchestra conductor Ronald Braunstein, diagnosed with bipolar disorder in 1985, co-founded the ME/2 Orchestra with his wife Caroline Whiddon in 2011 to create a welcoming performance environment for musicians with mental illness while raising public awareness.

• 7. History of a Diagnosis

  ›

  In the early 1800s, French psychiatrist Jean-Etienne Dominique Esquirol introduced the concept of lypemania, one of his affective monomanias, which laid early groundwork for what would become the modern understanding of depression. The conceptual foundation of bipolar illness as it is understood today traces to the 1850s.

  In 1850, Jean-Pierre Falret described what he called circular insanity, la folie circulaire, a pattern of recurrent swings between mania and depression. A lecture summary appeared in 1851 in the Gazette des hopitaux. Three years later, in 1854, Jules-Gabriel-Francois Baillarger, born in 1809, described to the French Imperial Academie Nationale de Medecine a biphasic mental illness he called la folie a double forme. His original paper appeared in the Annales medico-psychologiques in the same year.

  German psychiatrist Emil Kraepelin, born in 1856, used Karl Kahlbaum's concept of cyclothymia to study the natural course of untreated patients. Kraepelin coined the term manic depressive psychosis, observing that acute episodes, whether manic or depressive, were typically followed by relatively symptom-free intervals in which the patient could function normally. In the 1920s, Kraepelin also noted that manic episodes are rare before puberty.

  The term manic-depressive reaction appeared in the first edition of the DSM in 1952, influenced by the work of Adolf Meyer. The division of mood disorders into unipolar and bipolar categories was grounded in Karl Kleist's framework developed from 1911 onward and was elaborated by Karl Leonhard in 1957. These subtypes were treated as separate conditions beginning with the DSM-III. The bipolar II diagnosis and rapid cycling specifier entered the DSM-IV in 1994, based on research from the 1970s by David Dunner, Elliot Gershon, Frederick Goodwin, Ronald Fieve, and Joseph Fleiss. World Bipolar Day is held on March 30, the birthday of Vincent Van Gogh, and is sponsored by the International Society for Bipolar Disorders, the International Bipolar Foundation, and the Asian Network of Bipolar Disorder.